Australia markets close in 33 minutes
  • ALL ORDS

    6,873.50
    +26.20 (+0.38%)
     
  • ASX 200

    6,644.00
    +28.70 (+0.43%)
     
  • AUD/USD

    0.7428
    -0.0011 (-0.15%)
     
  • OIL

    46.34
    +0.70 (+1.53%)
     
  • GOLD

    1,845.80
    +4.70 (+0.26%)
     
  • BTC-AUD

    25,903.52
    +6.40 (+0.02%)
     
  • CMC Crypto 200

    377.88
    +3.47 (+0.93%)
     
  • AUD/EUR

    0.6114
    -0.0008 (-0.12%)
     
  • AUD/NZD

    1.0520
    +0.0009 (+0.09%)
     
  • NZX 50

    12,631.38
    -17.53 (-0.14%)
     
  • NASDAQ

    12,467.13
    +10.72 (+0.09%)
     
  • FTSE

    6,490.27
    +26.88 (+0.42%)
     
  • Dow Jones

    29,969.52
    +85.73 (+0.29%)
     
  • DAX

    13,252.86
    -60.34 (-0.45%)
     
  • Hang Seng

    26,686.54
    -41.96 (-0.16%)
     
  • NIKKEI 225

    26,711.70
    -97.67 (-0.36%)
     

RETA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Reata Pharmaceuticals, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm

Bronstein, Gewirtz & Grossman, LLC
·2-min read

NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. ("Reata" or "the Company") (NASDAQ: RETA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Reata securities between October 15, 2019 and August 7, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/reta.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (2) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/reta or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Reata you have until December 14, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com